?Evaluation of specific antibody titre against Pneumococcus in patients with Ataxia-telangiectasia and IgA deficiency

Determination of specific antibody titre against Pneumococcus and its relation with recurrent infection in patients with ataxia-telangiectasia and IgA deficiency

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190508043517N1

Enrollment

100

Registered

2019-06-17

Start date

2019-05-08

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Ataxia-telangiectasia. Condition 2: IgA deficiency. Cerebellar ataxia with defective DNA repair Selective deficiency of immunoglobulin A [IgA]

Interventions

One-half-milliliter dose of non-conjugate pneumococcal polyvalent vaccine (PNEUMO 23® Aventis, Pasteur, France).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with selective IgA deficiency and ataxia-telangiectasia based on defined criteria

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ataxia-telangiectasia. Timepoint: Before intervention. Method of measurement: According to the ESID diagnostic criteria.;IgA deficiency. Timepoint: Before intervention. Method of measurement: According to the ESID diagnostic criteria.;Sex. Timepoint: Before intervention. Method of measurement: Questionnaire.;Age. Timepoint: Before intervention. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Determination of the pneumococcus specific antibodies level. Timepoint: Before and after intervention. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Sohani

Tehran University of Medical Sciences

sohanimahsa1369@gmail.com+98 21 6612 9187

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026